Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study (MEKANOS)

Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT (Computed Tomography) : the MEKANOS Study

Osteolytic bone metastases and myeloma bone lesions are responsible of long bone and vertebral fractures leading to restricted mobility, surgery and medullar compression that severely alter quality of life and that have a huge medico-economic impact. It has been estimated that 50% of the patients with bone metastasis will encounter bone complications. In the recent years, Bone Oncology Multidisciplinary Meetings have been developed to optimize bone metastases management for each patient in harmony with oncology program.

The assessment of the fracture risk of bone metastasis remains fairly empirical and is based on simple radiography. The Mirel's score for long bones is focused on the extent of cortical defect caused by bone metastasis to identify high-risk patients at risk of fracture during surgery. It is old, little used in routine and lacks sensitivity and specificity. The SINS (Spinal Instability Neoplastic Score) score is the reference for vertebrae. Today, most patients with fracture-risk bone metastasis benefit from a lesion-centered CT scan to better characterize its extent and position but the interpretation remains qualitative. Metastases are considered as an air cavity and the mechanical properties of the tumor are not evaluated. However, many other parameters from the CTscan are available such as cortical or trabecular compartment densitometry, cortical thickness, tumor volume, and position of lysis in the bone.

Based on experience acquired by the service in the evaluation of bone mechanical strength on benign bones, the investigator aim at integrating in the numerical simulation the mechanical properties of both bone and tumor, in order to evaluate the mechanical strength of the pathological bone using a numerical simulation model (finite element analysis-FEA).

MEKANOS will enroll patients with bone metastases of breast, lung, kidney, thyroid or bladder cancer and myeloma lesions affecting the vertebrae or the upper end of the femur.

The resistance obtained will be compared to that of an intact bone. The best predictive parameters of mechanical strength (position of lysis, tumor nature, and bone architecture) will be then determined. Finally, the added value of this technique in relation to historical fragility scores (Mirel's and SINS scores) will be assessed.

The ultimate goal is to provide tools to assess fracture risk and improve the preventive management of bone metastases in harmony with the referring oncologist

Study Overview

• Status: Recruiting
• Conditions: Metastatic Breast Cancer; Metastatic NSCLC; Metastases to Bone
• Intervention / Treatment: Other: Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation

• Study Type: Observational
• Enrollment (Estimated): 220

Contacts and Locations

• Study Contact: Name: Cyrille CONFAVREUX, PR; Phone Number: +33 4.78.86.12.31; Email: cyrille.confavreux@chu-lyon.fr
• Study Contact Backup: Name: Sara CALATTINI; Phone Number: +33 4.78.86.37.79; Email: sara.calattini@chu-lyon.fr

Study Locations

• France
  • Angers, France, 49100
    • Recruiting
    • Service de rhumatologie, CHU d'Angers
    • Contact: Béatrice BOUVARD; Phone Number: +33 2 41 35 35 76; Email: bebouvard@chu-angers.fr
  • Annecy, France, 74000
    • Recruiting
    • Ch Annecy Genevois
    • Contact: Frédérique ORSINI-PIOCELLE; Phone Number: 0450636144; Email: forsinipiocelle@ch-annecy-genevois.fr
  • Clermont-Ferrand, France, 63011
    • Recruiting
    • Service de radiothérapie, Institut Jean-Perrin
    • Contact: Aurélie BELLIERE; Phone Number: +33 4 73 27 81 42; Email: aurelie.belliere@laposte.net
  • Contamine-sur-Arve, France, 74130
    • Recruiting
    • Service de rhumatologie, CH Annemasse
    • Contact: Arnaud MAZOUYES; Phone Number: +33 4 50 82 29 81; Email: amazouyes@ch-alpes-léman.fr
  • Lille, France, 59000
    • Recruiting
    • Service d'onco-rhumatologie, Centre Oscar Lombret
    • Contact: Marie-Hélène VIEILLARD; Phone Number: +33 3 20 44 40 58; Email: mh-vieillard@chru-lille.fr
  • Lyon, France, 69008
    • Recruiting
    • Service de Radiothérapie, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian
    • Contact: Line CLAUDE; Phone Number: +33 4 78 78 26 49; Email: line.claude@lyon.unicancer.fr
  • Paris, France, 75014
    • Recruiting
    • Service d'oncologie médicale, Institut Curie, 26 rue d'Ulm
    • Contact: Nicolas GIRARD; Phone Number: +33 1 56 61 62 50; Email: nicolas.girard2@curie.fr
  • Paris, France, 75014
    • Recruiting
    • Service de Radiologie, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris
    • Contact: Antoine FEYDY; Phone Number: +33 1 58 41 24 83; Email: antoine.feydy@aphp.fr
  • Pierre-Bénite, France, 69310
    • Recruiting
    • Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud
    • Contact: Cyrille CONFAVREUX, PR; Phone Number: +33 4 78 86 12 31; Email: Cyrille.confavreux@chu-lyon.fr
  • Poitiers, France, 86021
    • Recruiting
    • Service de rhumatologie, CHU de Poitiers
    • Contact: Guillaumd LARID; Phone Number: +33 05 49 44 44 65; Email: guillaume.larid@chu-poitiers.fr
  • Saint-Priest-en-Jarez, France, 42270
    • Recruiting
    • Service de rhumatologie, CHU de Saint Etienne
    • Contact: Thierry THOMAS; Phone Number: +33 4 77 12 76 42
    • Contact: Karima BOUSSOUALI; Phone Number: +33 4 77 12 76 42; Email: Karima.boussoualim@chu-st-etienne.fr
  • Vandoeuvre-lès-Nancy, France, 54500
    • Recruiting
    • Institut de Cancerologie de Lorraine
    • Contact: Selima SELLAMI; Phone Number: 03 83 59 84 00; Email: s.sellami@nancy.unicancer.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with predominantly osteolytic tumor involvement related either to myeloma or bone metastases of lung, breast, bladder, thyroid or kidney cancer.

Description

Inclusion Criteria:

• Adult patients (> 18 years of age).
• Patients who do not object to participating in the study. For patients participating to the biological collection: signature of the written informed consent..
• Patients with secondary tumor lesion(s) of mammary or pulmonary non-small cell, renal, bladder, thyroid or myeloma bone origin.
• Existence of a CT scan focused on the target lesion (or which will be performed as part of the care), performed within a time window of 30 days before and 20 days after inclusion, as part of the patient's usual bone management.
• Target location: upper end of the femur (1/3 proximal) and/or vertebrae. Several locations are possible for the same patient, provided that the inclusion criteria are met for each target.
• Size of target lesion: either diffuse permeative or > 15 mm in size.
• Exposure to systemic bone therapy for 3 months or less (daily clodronate or denosumab, zoledronic acid, monthly pamidronate) is allowed
• Patients who received previous systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) are eligible.

Exclusion Criteria:

• Patients who have received targeted treatment at the target location either in the form of radiotherapy, surgery or interventional radiology (cementoplasty, cryotherapy, radiofrequency).
• Fractured pathological target bone.
• For the femur target, the patient must not have a hip prosthesis on either side (target or contralateral)
• Patients under trusteeship.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Patients with bone metastases at risk of fracture; Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency…). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) and bone treatments are allowed if administered for less than 3 months.

Other: Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation; Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of mechanical strength of tumor proximal femur or tumor vertebrae obtained by numerical simulation using the finite element analysis (FEA) method.	Measurement of mechanical strength (expressed in Newton : N), monopodal support at the upper end of the femur and uniaxial compression on the vertebrae, obtained by numerical simulation using the finite element analysis (FEA) method. As an indication, the average resistance of a femur of an elderly patient in monopod support is on average 9000 N and that of the L3 vertebra in uniaxial compression is on average 2700 N. Comparative values will also be obtained on the healthy contralateral femur and an adjacent healthy vertebra of each patient	24 months

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon
• Investigators: Principal Investigator: Cyrille CONFAVREUX, PR, Service de Rhumatologie

Study record dates

Study Major Dates

• Study Start (Actual): November 28, 2019
• Primary Completion (Estimated): November 28, 2026
• Study Completion (Estimated): November 28, 2026

Study Registration Dates

• First Submitted: November 18, 2019
• First Submitted That Met QC Criteria: November 18, 2019
• First Posted (Actual): November 20, 2019

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 11, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: femur; vertebrae; osteolytic secondary tumoral lesion; qCT routine imagery
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Neoplasm Metastasis
• Other Study ID Numbers: 69HCL17_0642

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No